# S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

> **NCT00075686** · PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 766 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00075686
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2007-05
- **Final completion:** 2009-04
- **Target enrollment:** 766 (ACTUAL)
- **Last updated:** 2015-11-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075686, "S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00075686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*